Results 101 to 110 of about 131,024 (143)

STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes. [PDF]

Neoplasia
King Z, Desai SR, Frank DA, Shastri A.
europepmc   +1 more source

Prognostic analysis of SYTL4 in acute myeloid leukemia. [PDF]

Transl Cancer Res
Xie KY, Wei J.
europepmc   +1 more source

Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia. [PDF]

Blood Adv
Brown FC, Wang X, Birkinshaw R, Chua CC, Morley T, Kasapgil S, Pomilio G, Blombery P, Huang DCS, Czabotar P, Priore SF, Yang G, Carroll M, Wei AH, Perl AE.   +14 more
europepmc   +1 more source

Identification of glucuronic acid as a biomarker of poor prognosis in acute myeloid leukemia based on plasma metabolomics. [PDF]

Clin Exp Med
Yang J, Wang Z, Wu K, Ruan J, Nie B, Zhou Q, Li L, Luo L, Zhang F, Shi M, Zeng Y.   +10 more
europepmc   +1 more source

Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024. [PDF]

Exp Hematol Oncol
Zhang H, Zhu HH.
europepmc   +1 more source

Editorial: Molecular MRD testing in patients with acute myeloid leukemia. [PDF]

Bone Marrow Transplant
Blackmon AL, Grunwald MR.
europepmc   +1 more source

The value of plasma sCD25 in diagnosis, therapeutic efficacy, and prognosis of acute myeloid leukemia. [PDF]

Clin Exp Med
Wang J, Zuo Y, Wang W, Xu J, Liu C, Jiang M.   +5 more
europepmc   +1 more source

Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia. [PDF]

Cancer Med
Liu Q, Zhang X, Lv L, Xu L, Jing Y, Gao W, Wang L, Dou L.   +7 more
europepmc   +1 more source

Therapy for acute myeloid leukemia in older and unfit adults. [PDF]

Haematologica
Forsberg M, Konopleva M.
europepmc   +1 more source